The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug
Open accessAbstract
SQ109 is a novel [1,2]‐diamine‐based ethambutol (EMB) analog developed from high‐throughput combinatorial screening. The present study aimed at characterizing its pharmacodynamics and pharmacokinetics. The antimicrobial activity of SQ109 was confirmed in vitro (Mycobacterium tuberculosis‐infected murine macrophages) and in vivo (M. tuberculosis‐infected C57BL/6 mice) and compared to isoniazid (INH) and EMB. SQ109 showed potency and efficacy in inhibiting intracellular M. tuberculosis that was similar to INH, but superior to EMB. In vivo oral administration of SQ109 (0.1–25 mg kg−1 day−1) to the mice for 28 days resulted in dose‐dependent reductions of mycobacterial load in both spleen and lung comparable to that of EMB administered at 100 mg kg−1 day−1, but was less potent than INH at 25 mg kg−1 day−1. Monitoring of SQ109 levels in mouse tissues on days 1, 14 and 28 following 28‐day oral administration (10 mg kg−1 day−1) revealed that lungs and spleen contained the highest concentration of SQ109, at least 10 times above its MIC. Pharmacokinetic profiles of SQ109 in mice following a single administration showed its Cmax as 1038 (intravenous (i.v.)) and 135 ng ml−1 (p.o.), with an oral Tmax of 0.31 h. The elimination t1/2 of SQ109 was 3.5 (i.v.) and 5.2 h (p.o.). The oral bioavailability was 4%. However, SQ109 displayed a large volume of distribution into various tissues. The highest concentration of SQ109 was present in lung (>MIC), which was at least 120‐fold (p.o.) and 180‐fold (i.v.) higher than that in plasma. The next ranked tissues were spleen and kidney. SQ109 levels in most tissues after a single administration were significantly higher than that in blood. High tissue concentrations of SQ109 persisted for the observation period (10 h). This study demonstrated that SQ109 displays promising in vitro and in vivo antitubercular activity with favorable targeted tissue distribution properties. British Journal of Pharmacology (2005) 144, 80–87. doi:10.1038/sj.bjp.0705984
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Cited by
Antituberculosis drugs: Ten years of research
Janin, Y. L. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.030 · Cited by 485
Confronting the scientific obstacles to global control of tuberculosis
Young, D. B., Perkins, M. D., Duncan, K., & Barry, C. E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34614 · Cited by 324
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., Phillips, P. P. J., Gillespie, S. H., McHugh, T. D., Hoelscher, M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1264oc · Cited by 309
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Discovery and Development of SQ109: A New Antitubercular Drug with a Novel Mechanism of Action
Sacksteder, K. A., Protopopova, M., Barry, C. E., Andries, K., & Nacy, C. A. (2012) · Future Microbiology · doi:10.2217/fmb.12.56 · Cited by 269
Self-citation
Metadata
- Authors
- Jia, L., Tomaszewski, J. E., Hanrahan, C., Coward, L., Noker, P., Gorman, G., Nikonenko, B., & Protopopova, M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-01
- Volume
- 144
- Issue
- 1
- Pages
- 80-87
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1540126244
- Cited by
- 231
- References
- 1
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug. https://app.cochat.ai/papers/10.1038/sj.bjp.0705984
- The paper
- Jia, L., Tomaszewski, J. E., Hanrahan, C., Coward, L., Noker, P., Gorman, G., Nikonenko, B., & Protopopova, M. (2005). Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0705984
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.